Cost-effectiveness analysis of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the US
{{output}}
Aim: The objective of this analysis was to evaluate the cost-effectiveness of xanomeline and trospium chloride (KarXT) as first line (1 L) treatment for adults with schizophrenia from a third-party US payer perspective compared w... ...
